hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC]
hydrocortisone acetate
RxCUI: 828364
What the CMS Formulary Data Shows for hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC]
Per the CMS 2026 Part D formulary file, hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] (RxNorm concept RXCUI 828364, generic name hydrocortisone acetate) appears on 14 distinct formulary files spanning 231 Medicare Part D plan offerings - 4.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.4.
Real-world access to hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 430 Part D beneficiaries filled hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] in 2023, with total plan-and-beneficiary spending of $527,716 and an average per-beneficiary annual cost of $1,227.25. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] today.
Coverage Details
- Formularies covering
- 14
- Plans covering
- 231
- Coverage rate
- 4.6%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 430
- Total spending
- $527,716
- Avg per beneficiary
- $1,227.25
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] covered by Medicare Part D?
Yes, hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] is covered by 231 Medicare Part D plans (4.6% of all Part D formularies).
What tier is hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] on Medicare Part D plans?
hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] averages Tier 2.4 across Part D plans, ranging from Tier 1 to Tier 4.
Does hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] require prior authorization?
0% of Part D formularies require prior authorization for hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC]?
In 2023, total Medicare Part D spending on hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Foam [Proctofoam-HC] was $527,716, covering 430 beneficiaries. The average spend per beneficiary was $1,227.25.
Read our methodology - how this data is sourced, computed, and verified.